Horne ZD, et al. - In the present study, researchers ascertained whether p16-positivity (a surrogate for human papillomavirus) predicts better response rates to chemoradiation therapy and survival by conducting a retrospective chart review of women treated with neoadjuvant or definitive chemoradiation (CRT) therapy from 2000 to 2016 for vulvar squamous cell carcinoma. In this investigation, 73 women (33 with p16+ tumors) with a median follow-up of 13.4 months were analyzed. The findings from the present study suggested that p16 expressing vulvar cancers seem to have better clinical and pathologic response rates and clinical outcomes. The complete clinical response rate for p16+ tumors was 63.6% vs 35.0% for p16− tumors.